Home Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial ...
 

Keywords :   


Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial ...

2015-06-01 20:27:17| Biotech - Topix.net

Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has begun enrolling patients in a Phase 2b clinical trial to evaluate Apricus' novel product candidate, fispemifene, a selective estrogen receptor modulator , for the treatment of men with symptomatic secondary hypogonadism also known as low testosterone. The Phase 2 proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in approximately 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone.

Tags: trial phase patients clinical

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
More »